Compare XENE & MPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XENE | MPT |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | Canada | United States |
| Employees | N/A | 118 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2014 | N/A |
| Metric | XENE | MPT |
|---|---|---|
| Price | $58.33 | $4.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 1 |
| Target Price | ★ $67.17 | $5.00 |
| AVG Volume (30 Days) | 1.1M | ★ 5.3M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.68% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,436.26 | $4.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.19 | $4.51 |
| 52 Week High | $62.91 | $6.47 |
| Indicator | XENE | MPT |
|---|---|---|
| Relative Strength Index (RSI) | 65.00 | 53.17 |
| Support Level | $39.93 | $4.53 |
| Resistance Level | $59.44 | $5.78 |
| Average True Range (ATR) | 1.86 | 0.12 |
| MACD | -0.17 | 0.07 |
| Stochastic Oscillator | 80.01 | 90.22 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.